Earnings Call · Q4 FY2021·2022-03-29

Q4 21EPS +100.00%*·Rev n/aQ3 21EPS -100.00%*·Rev n/aQ2 21EPS -35.71%·Rev n/aQ1 21EPS +77.78%·Rev n/a⚠ consensus missing

Humacyte, Inc. HUMA

Disclaimer*

Lauren Marek — Investor Relations

Laura Niklason — Chief Executive Officer

Dale Sander — Chief Financial Officer

+5.7%1d on move date+4.4% vs SPY3d+10.8%5d+8.3%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more HUMA calls or request research access.

More HUMA calls Browse calls Request research access